Bulk Pharmaceutical API Sources for PRECOSE

Bulk Pharmaceutical API Sources for PRECOSE

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A830944
AbaChemScene		CS-1787
MedChemexpress MCE		HY-B0089
BOC Sciences		56180-94-0

PRECOSE (ACARBOSE) BULK API SOURCES

Last updated: February 19, 2026

Acarboase, marketed as PRECOSE, is an alpha-glucosidase inhibitor used to manage type 2 diabetes. Its bulk active pharmaceutical ingredient (API) is sourced globally, with key manufacturing hubs in China and India. This analysis identifies primary API suppliers, patent landscape, and regulatory considerations impacting the PRECOSE supply chain.

What is the Global Supply Landscape for Acarboase API?

The global supply of acarbose API is dominated by manufacturers in Asia, primarily China and India, known for their cost-effective production capabilities. Several companies in these regions have established manufacturing processes and supply agreements with generic drug formulators worldwide.

Key API Manufacturers and Suppliers:

• China:
  • Jiangsu Hanxiang Pharmaceutical Co., Ltd.: A significant producer with established Good Manufacturing Practice (GMP) compliance.
  • Anhui Fengyuan Pharmaceutical Co., Ltd.: Another major Chinese supplier with a broad portfolio of APIs, including acarbose.
  • Zhejiang Medicine Co., Ltd.: Known for pharmaceutical intermediates and APIs, with acarbose listed in its product catalog.
• India:
  • Divi's Laboratories: A prominent Indian API manufacturer with a strong global presence and regulatory approvals.
  • Laurus Labs: Specializes in APIs and finished dosage forms, with acarbose as part of its therapeutic offerings.
  • Aurobindo Pharma: A large pharmaceutical company with API manufacturing capabilities across various therapeutic areas.
• Other Regions: While less prominent, some European and North American companies may produce or distribute acarbose API, often focusing on specialized or higher-purity grades. However, cost pressures generally favor Asian manufacturing for bulk supply.

The availability and pricing of acarbose API are influenced by raw material costs, manufacturing capacity, and regulatory hurdles in originating countries. Manufacturers typically require extensive documentation, including Drug Master Files (DMFs), to support customer regulatory submissions.

What is the Patent Landscape for Acarboase?

The original patent protection for acarbose has long expired, allowing for generic competition. However, patents related to new formulations, manufacturing processes, or polymorphs can still exist, potentially impacting market entry for new generic players or offering protection for innovator companies against specific manufacturing methods.

Key Patent Expirations and Generic Entry:

• Original Composition of Matter Patent: Expired in the early 2000s, enabling widespread generic manufacturing.
• Manufacturing Process Patents: Various patents have been filed and expired relating to specific synthesis routes, purification techniques, and polymorphic forms of acarbose. For instance, patents concerning novel crystallization methods or improved yield processes may have offered temporary protection.
• Formulation Patents: Innovator companies have historically sought patents for novel drug delivery systems or combination therapies involving acarbose. These can extend market exclusivity for specific product types.

Active Patent Filings and Strategies:

Companies continuously file patents to protect incremental innovations. These may include:

• New Polymorphs: Different crystalline structures of acarbose can affect solubility, stability, and bioavailability, leading to patentable variations.
• Improved Synthesis Routes: Patents might cover more efficient, environmentally friendly, or cost-effective methods for producing acarbose API.
• Controlled-Release Formulations: Developments in extended-release or targeted-release versions of acarbose can be patented.

A thorough patent search is crucial for any new market entrant to identify freedom-to-operate issues and potential infringement risks. This includes analyzing patents filed by competitors and established players.

What are the Regulatory Requirements for Acarboase API?

Regulatory compliance is paramount for acarbose API manufacturing and distribution. This includes adherence to GMP standards, robust quality control, and the submission of comprehensive regulatory dossiers.

Key Regulatory Bodies and Requirements:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying acarbose API to the U.S. market must comply with 21 CFR Part 210 and 211 (Current Good Manufacturing Practice). A DMF submission is typically required for the API.
• European Medicines Agency (EMA): API manufacturers must adhere to EudraLex Volume 4 – GMP guidelines. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often sought.
• Pharmaceuticals and Medical Devices Agency (PMDA) Japan: Strict GMP compliance and dossier submission are required.
• Other National Agencies: Each country has its specific regulatory requirements, often aligning with ICH (International Council for Harmonisation) guidelines.

Quality Standards and Testing:

• Pharmacopoeial Compliance: Acarbose API must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), and Japanese Pharmacopoeia (JP).
• Impurity Profiling: Rigorous testing for related substances, residual solvents, and elemental impurities is mandatory.
• Stability Studies: Comprehensive stability data is required to establish re-test periods and storage conditions.

DMF Submissions:

Drug Master Files (DMFs) are confidential detailed documents submitted to regulatory authorities by API manufacturers. These contain comprehensive information about the manufacturing process, facility, quality control, and stability of the API. The DMF allows regulatory agencies to review the API information in support of customer drug product applications without disclosing proprietary details to the customer.

What are the Key Considerations for Sourcing Acarboase API?

Sourcing acarbose API involves evaluating supplier reliability, quality assurance, pricing, and supply chain resilience.

Supplier Evaluation Criteria:

• GMP Compliance and Audits: Verification of current GMP certification and successful completion of regular facility audits by customers or third parties.
• Regulatory Track Record: History of successful DMF submissions and inspections by major regulatory agencies (FDA, EMA).
• Quality Control Systems: Robust in-house quality control laboratories and established procedures for batch release testing.
• Production Capacity and Lead Times: Assessment of the supplier's ability to meet volume demands and provide reliable delivery schedules.
• Cost Competitiveness: Balancing price with quality and reliability.
• Supply Chain Transparency: Understanding the origin of raw materials and the manufacturing process.
• Intellectual Property (IP) Risk: Ensuring the supplier operates with freedom to supply the API without infringing existing process patents.

Risk Mitigation Strategies:

• Dual Sourcing: Engaging with multiple qualified API suppliers to mitigate risks associated with single-source dependency.
• Long-Term Contracts: Establishing agreements that ensure stable pricing and supply commitments.
• Regular Quality Audits: Conducting ongoing audits to ensure continued adherence to quality standards.
• Geopolitical Risk Assessment: Monitoring the political and economic stability of manufacturing regions.
• Inventory Management: Maintaining adequate buffer stock to account for potential supply chain disruptions.

The choice of an API supplier significantly impacts the cost of goods, product quality, and the speed of regulatory approval for finished dosage forms.

What are the Economic Drivers for Acarboase API Pricing?

Acarboase API pricing is influenced by a combination of manufacturing costs, market demand, and competitive pressures.

Cost Components:

• Raw Material Costs: Prices of key starting materials and intermediates used in the synthesis of acarbose.
• Manufacturing Expenses: Labor, energy, facility overhead, and waste disposal costs.
• Quality Control and Regulatory Compliance: Expenses associated with analytical testing, validation, and DMF maintenance.
• Research and Development (R&D): Costs for process optimization and development of new polymorphic forms or synthetic routes.

Market Demand and Competition:

• Generic Market Penetration: The prevalence of generic acarbose products globally drives demand for cost-effective API.
• Therapeutic Area Growth: Increasing prevalence of type 2 diabetes globally contributes to sustained demand.
• Competitive Landscape: The number of qualified API manufacturers and their respective market shares influence pricing power. Intense competition among suppliers, particularly from China and India, tends to exert downward pressure on prices.

Supply Chain Factors:

• Geographic Concentration: Reliance on specific regions for manufacturing can create vulnerabilities to local regulatory changes, environmental policies, or geopolitical events, which can impact pricing.
• Logistics and Transportation: Costs associated with shipping API globally, including freight rates and import duties.

Price fluctuations can occur due to changes in raw material availability, currency exchange rates, and shifts in regulatory landscapes.

Key Takeaways

• The global supply of acarbose API is concentrated in China and India, with several established manufacturers adhering to international GMP standards.
• The original patents for acarbose have expired, facilitating generic market entry, though patents on specific processes or formulations may still exist.
• Regulatory compliance, including GMP adherence and DMF submissions to bodies like the FDA and EMA, is critical for API suppliers.
• Key sourcing considerations include supplier quality, regulatory history, production capacity, and cost-effectiveness, with dual sourcing recommended for risk mitigation.
• Acarbose API pricing is driven by manufacturing costs, global demand for diabetes medications, and intense competition among suppliers.

Frequently Asked Questions

1. What are the primary impurities to monitor in acarbose API? Impurities to monitor typically include related substances (e.g., degradation products, process-related byproducts), residual solvents, and elemental impurities, as defined by pharmacopoeial monographs and ICH guidelines.
2. How is the stability of acarbose API typically assessed? Stability is assessed through accelerated and long-term studies under defined temperature and humidity conditions, monitoring parameters such as assay, impurity levels, and physical appearance according to ICH Q1A(R2) guidelines.
3. What is the typical shelf life or re-test period for acarbose API? Typical re-test periods for acarbose API can range from 2 to 5 years, depending on the specific manufacturing process, packaging, and stability data generated, as approved by regulatory authorities.
4. Are there any specific environmental regulations that impact acarbose API manufacturing? Manufacturers must comply with local environmental regulations concerning wastewater treatment, air emissions, and hazardous waste disposal, which can vary significantly by manufacturing location.
5. What is the impact of pharmacopoeial updates on acarbose API suppliers? Suppliers must continually monitor and adapt to updates in pharmacopoeial monographs (e.g., USP, Ph. Eur., JP) for acarbose, ensuring their API consistently meets revised specifications for quality and purity.

Citations

[1] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 210 - Current Good Manufacturing Practice In Manufacturing, Processing, Packing, Or Holding Of Drugs; General. U.S. Government Publishing Office. [2] U.S. Food and Drug Administration. (n.d.). 21 CFR Part 211 - Current Good Manufacturing Practice For Finished Pharmaceuticals. U.S. Government Publishing Office. [3] European Medicines Agency. (2010). EudraLex Volume 4 – GMP guidelines. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Impurities: Guideline for Residual Solvents Q3C(R4). [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2006). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2). [6] United States Pharmacopeia. (n.d.). Acarbose. USP-NF. [7] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP).